AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in several upcoming virtual investor conferences. Jon Lieber, CFO, will present at the 34th Annual ROTH Conference on March 13-15, 2022. Sue Washer, President and CEO, will be on a panel at the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on March 29, 2022, discussing gene therapy for rare diseases. Additionally, a fireside chat with Ms. Washer will be held at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. Replays of the events will be available on the Company's website.
- None.
- None.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that management will be participating in the following virtual investor conferences:
- 34th Annual ROTH Conference (March 13 - 15, 2022)
A presentation by Jon Lieber, Chief Financial Officer, is now available to view on-demand.
- Cantor Fitzgerald Virtual Rare Orphan Disease Summit (March 29, 2022)
Sue Washer, President and Chief Executive Officer, will be participating in a panel discussion entitled “Gene Therapy Pioneers: Why Experience Matters When Targeting Rare Diseases.” The panel discussion will begin at 4:00 p.m. ET.
- H.C. Wainwright Gene Therapy and Gene Editing Conference (March 30, 2022)
A fireside chat with Ms. Washer will be available to view on-demand beginning at 7:00 a.m. ET.
Audio webcasts of the presentations and panel discussion can be accessed by visiting http://ir.agtc.com/events-and-presentations. Replays will be available on the Company's website following the events.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3) leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, and has entered into strategic collaborations with companies including Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. For more information, please visit https://agtc.com/.
IR Contact:
David Carey
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com
Corporate Contact:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
FAQ
What conferences is AGTC participating in March 2022?
Who is presenting at the ROTH Conference for AGTC?
What is the topic of the panel at the Cantor Fitzgerald Summit?
When will the fireside chat with Sue Washer be available?
Where can I access the webcasts of AGTC's presentations?
